OBJECTIVES: This study aimed to assess clinical efficacy of three adjuvant chemotherapy regimens, namely i) Mayo clinic regimen (5-fluorouracil and leucovorin, 5FU/LV), ii) FOLFOX4 (oxaliplatin plus 5-FU/LV), and iii) oral capecitabine for treatment of patients with stage III colon cancer.  METHODS:  A systematic review of randomized controlled trials (RCTs), and meta-analysis of RCT of adjuvant chemotherapy for patients with stage III colon cancer were included by searching through the Medline and Cochrane databases. The clinical efficacy studies of three adjuvant chemotherapy regimens on improving survival outcomes of patients with stage III colon cancer were included. Indirect or mixed-treatment comparison meta-analysis with fix effect model was applied to combine results of several studies. The meta-analysis was carried out using Bayesian approach and WinBUGS14 software program. The summary efficacy of adjuvant chemotherapy were presented as Odds ratio (OR) and its 95% confidence interval (CI). To test the variation of study outcomes between studies, heterogeneity test was also applied.     RESULTS: Total of 714 abstracts were reviewed and four eligible studies related to adjuvant chemotherapy for patients with stage III colon cancer were included in the meta-analysis. Two studies compared oral capectitabine with 5-FU/LV, while one study compared FOLFOX4 with 5-FU/LV. Indirect comparison was used to compare FOLFOX 4 and oral capecitabine. When compared to 5-FU/LV, FOLFOX4 and oral capecitabine could significantly reduce the risk of death by 23% (OR=0.77, 95%CI= 0.68-0.86) and 16% (OR=0.84, 95%CI= 0.72- 0.98), respectively. Moreover, the OR of mortality among patients treated by oxaliplatin plus 5-FU/LV was 0.92 (95%CI= 0.76-1.11) compared to capecitabine.   CONCLUSIONS: Of three regimens for patients with adjuvant chemotherapy stage III colon cancer, FOLFOX4 could significantly yield the longest patient survival, followed by capecitabine and 5-FU/LV. However, FOLFOX4 did not significantly reduce mortality events compared with capecitabine.